AIG is also investing heavily in technology, building a world-class platform that will provide the company with quality data and the ability to accurately project risk out into the future. This is something the regulators will be happy to see, Benmosche added.
Cramer said AIG is the cheapest of all the insurers he follows.
More 'Final Four'
For the second installment of his "Final Four" tribute to NCAA basketball's "March Madness," Cramer moved to the Nasdaq bracket where the contenders, Intercept Pharmaceuticals (ICPT - Get Report) and Fuel Cell Technologies (PLUG - Get Report) were duking it out to see which makes the final matchup Friday.
Cramer said any investors who own these stocks have had a remarkable run and should sell three-quarters of their positions to lock in their gains.
As for the matchup, Cramer said Intercept's liver disease treatments are very promising and their orphan status with the Food and Drug Administration makes them very attractive. That said, approvals for the company's first and second drugs are pretty much priced into the stock at these valuations.
Fuel Cell, on the other hand, has a sizable backlog of orders for its forklift power systems, with a notable customer that's none other than Wal-Mart (WMT). This company needs a steady stream of positive news to keep it going, said Cramer, which makes it worrisome.
After careful evaluation of both companies, Cramer said he's declaring Intercept the winner in the Nasdaq bracket, and the company will face off against last night's winner, oil driller Nabors Industries (NBR).